ASCO 2022: Circulating Tumour Cells (CTCs) and PSMA PET Correlates in the Phase I PRINCE Trial of 177Lu-PSMA-617 plus Pembrolizumab for Metastatic Castration Resistant Prostate Cancer (mCRPC)

(UroToday.com) As now increasingly appreciated, PSMA-targeted radionuclides are safe and effective therapies in metastatic castration resistant prostate cancer (mCRPC). Despite this, there are approximately half of patients in the published large studies (e.g. TheraP, VISION) who do not experience a significant PSA decline. Whether due to patient selection, mechanism of targeting, or radionuclide, ongoing work is active to enhance the efficacy of PSMA-TRTs for more patients. To this goal, the phase I PRINCE study was launched to evaluate the safety and efficacy of 177Lu-PSMA-617 in combination with an immune checkpoint inhibitor (pembrolizumab) in mCRPC.


In an effort to elucidate markers of resistance or susceptibility, the authors evaluated circulating tumor cells (CTC), both number and low pass whole genome single cell sequencing for evaluation of copy number alterations (CNAs). Also evaluated were quantitative PET CT metrics including molecular tumor volume (MTV) and total lesional activity (TLA), defined as the product of MTV and SUVmean. Associations between these metrics were tested with Each of these was evaluated for association via Spearman correlation.

Reproduction of the study schema was provided for orientation and illustration of sample collection kinetics. PSMA PET imaging was collected at baseline, followed by every 12 weeks (through 48 weeks), and then every 24 weeks thereafter. CTC characterization was performed via Epic Sciences on baseline and week 12 blood collections. 36 of 37 patients were evaluable for these endpoints. 

ASCO PRINCE study-0.jpg

CTCs were detected in 32 of 36 patients (89%) with a median of 7 CTCs/3 mL of blood (range 0-554) with 23 (64%) being PSMA+ (median 1, range 0-224) at baseline. Changes from baseline, including clearance (decrease in CTC count by 100%), decrease, and increase were evaluated and illustrated in a bar plot.

PRINCE study-1.jpg

Baseline PSMA+ CTC count was noted to correlate with PET MTV (r s = 0.57, p<0.001) and TLA (r s = 0.87, p<0.001). Among the 18 patients with baseline CTCs evaluable for CNAs, frequent copy number loss was observed in aggressive-variant associated genes PTEN, TP53, and RB1.

PRINCE study-2.jpg

Quantitation of PSMA PET signal demonstrated parallel changes in PSMA+ CTC count with PET MTV and TLA, including clearance of PSMA+ CTCs by week 12. Clearance of these CTCs by week 12 following initiation of treatment was associated with an improvement in PSA PFS and radiographic PFS, as compared to those patients without clearance of CTC count burden.

PRINCE study-3.jpg

PRINCE study-4.jpg

The authors also included a case study of a patient with initial treatment response, based on conventional metrics (PSA and CTC decline) as well as exploratory use of serial PSMA PET. This powerful illustration of how each of these markers reflects a lockstep evaluation of disease burden supports the use of such metrics in clinical evaluation.

PRINCE study-5.jpg

The authors summarized the conclusions of their study as stating that PSMA PET-positive mCRPC is associated with decline in PSMA+ CTC count following treatment with 177Lu-PSMA-617 plus pembrolizumab. These changes are in parallel with measurement of PSMA PET-avid tumor quantitation (MTV/TLA). Perhaps as an indication how these data could be best used in the future to aid in evaluation of PSMA-TRT activity, early changes in PSMA+ CTCs and MTV/TLA were associated with outcomes. 

Presented by: Anis Hamid, MBBS, Eastern Health and University of Melbourne, Melbourne, Australia



Written by: Jones Nauseef, MD, PhD, Assistant Professor of Medicine within the Division of Hematology and Medical Oncology, Sandra and Edward Meyer Cancer Center, and Englander Institute for Precision Medicine Weill Cornell Medicine and Assistant Attending physician at NewYork-Presbyterian Hospital. @DrJonesNauseef on Twitter during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, Fri, June 3 – Mon, June 7, 2022. 

email news signup